2022
Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.Peer-Reviewed Original ResearchConceptsProstate cancer screeningUS Preventive Services Task ForcePSA testingCancer screeningInterrupted time series analysisCohort studyUS Preventive Services Task Force (USPSTF) recommendationDraft statementLarge national cohort studyEligible beneficiariesPSA testing ratesRetrospective cohort studyRate of PSANational cohort studyProstate-specific antigenAge-adjusted ratesTask Force recommendationsUSPSTF guidelinesMedian ageGuideline changesProstate cancerMedian numberMAIN OUTCOMEClaims dataTesting rates
2020
Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening
Yang DX, Makarov DV, Gross CP, Yu JB. Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening. Cancer Control 2020, 27: 1073274820902267. PMID: 32003227, PMCID: PMC7003204, DOI: 10.1177/1073274820902267.Peer-Reviewed Original ResearchMeSH KeywordsAgedEarly DiagnosisHumansIncidenceMaleMass ScreeningProstate-Specific AntigenProstatic NeoplasmsConceptsMetastatic prostate cancer incidenceProstate cancer incidenceHealth care service areasMetastatic diseaseCancer incidenceNational Cancer Institute's SurveillanceEnd Results (SEER) databaseLocalized prostate cancerSEER 18 registriesProstate-specific antigenPSA screeningLocalized diseaseResults databaseProstate cancerOlder menMetastatic incidenceIncidenceDiseaseDiagnosisLate changesMenRecent increaseAssociationRegistryCancer